<DOC>
	<DOCNO>NCT02207309</DOCNO>
	<brief_summary>This trial compare pazopanib placebo maintenance treatment 2 year patient retroperitoneal visceral high-risk soft tissue sarcoma multimodal treatment include prior neo- and/or adjuvant doxorubicin / ifosfamide chemotherapy regional hyperthermia .</brief_summary>
	<brief_title>Pazopanib Maintenance Phase II</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<criteria>Subjects must provide write informed consent prior performance studyspecific procedures assessment must willing comply treatment follow Patients must histological evidence highgrade soft tissue sarcoma ( grade 2 3 ) accord FNLCC grading system , tumor size ≥ 5 cm deep localization regard superficial fascia , exclude follow tumor type : Embryonal rhabdomyosarcoma Chondrosarcoma ( exclude extraskeletal myxoid chondrosarcoma ) Osteosarcoma ( exclude extraskeletal osteosarcoma ) Ewing tumor / primitive neuroectodermal tumor ( PNET ) Gastrointestinal stromal tumor ( GIST ) Dermatofibrosarcoma protuberans Patients undergone previous surgery inadequate margin ( tumourfree margin ≤1 cm margin contaminate ) eligible thermochemotherapy start within 8 week surgery Unstained slide ideally tumour block must available histological central review Completed 4 8 cycle thermochemotherapy doxorubicin ifosfamide least 21 day 42 day prior study entry No evidence disease follow completion firstline thermochemotherapy within ≤ 21 day study entry Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 No prior chemotherapy except thermochemotherapy doxorubicin ifosfamide Adequate organ system function No prior concurrent second primary malignant tumor ( except adequately treat situ carcinoma cervix , basal cell carcinoma ) No symptomatic know Central nervous system ( CNS ) metastases baseline Clinically significant gastrointestinal abnormality may increase risk gastrointestinal bleeding include , limited : Active peptic ulcer disease Known intraluminal metastatic lesion/s risk bleed Inflammatory bowel disease ( e.g . ulcerative colitis , Chrohn 's disease ) , gastrointestinal condition increase risk perforation History abdominal fistula , gastrointestinal perforation , intra abdominal abscess within 28 day prior begin study treatment . Clinically significant gastrointestinal abnormality may affect absorption investigational product include , limited : Malabsorption syndrome Major resection stomach small bowel . Corrected QT interval ( QTc ) &gt; 480 msecs History one follow cardiovascular condition within past 6 month : Cardiac angioplasty stenting Myocardial infarction Unstable angina Coronary artery bypass graft surgery Symptomatic peripheral vascular disease Class III IV congestive heart failure , define New York Heart Association ( NYHA ) ( See Appendix D description ) Poorly control hypertension ( SBP ≤ 150 mmHg DBP ≤95 mmHg acceptable provided BP treat monitor least weekly . The goal attain control hypertension within 4 week start IMP define grade ≤1 hypertension CTCAE Version 4.0 ) NYHA II Screening Patients &gt; 65 year History cerebrovascular accident include transient ischemic attack ( TIA ) , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month . Note : Subjects recent DVT treat therapeutic anticoagulating agent least 6 week eligible Major surgery trauma within 28 day prior first dose investigational product and/or presence nonhealing wound , fracture , ulcer ( procedure catheter placement consider major surgery ) . Evidence active bleeding bleed diathesis . Known endobronchial lesion and/or lesion infiltrate major pulmonary vessel increase risk pulmonary hemorrhage Note : Lesions infiltrate major pulmonary vessel ( contiguous tumour vessel ) exclude ; however , presence tumor touching , infiltrate ( abut ) vessel acceptable ( CT contrast strongly recommend evaluate lesion ) . Large protrude endobronchial lesion main lobar bronchus exclude ; however , endobronchial lesion segment bronchus allow . Lesions extensively infiltrate main lobar bronchus exclude ; however , minor infiltration wall bronchus allow . Recent hemoptysis ( ≥½ teaspoon red blood within 8 week first dose study drug ) . Any serious and/or unstable preexist medical , psychiatric , condition could interfere subject 's safety , provision inform consent , compliance study procedure . Treatment follow anticancer therapy : radiation therapy , surgery tumor embolization within 14 day prior first dose pazopanib OR chemotherapy , immunotherapy , biologic therapy , investigational therapy hormonal therapy within 14 day five halflives drug ( whichever longer ) prior first dose pazopanib Administration nononcologic investigational drug within 30 day 5 half life whichever longer prior receive first dose study treatment Any ongoing toxicity prior anticancer therapy &gt; Grade 1 and/or progress severity , except alopecia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>high-risk soft tissue sarcoma</keyword>
	<keyword>pazopanib</keyword>
	<keyword>retroperitoneal soft tissue sarcoma</keyword>
	<keyword>visceral soft tissue sarcoma</keyword>
	<keyword>votrient</keyword>
</DOC>